新型小分子示踪剂 68Ga-NY104 PET/CT评估von Hippel-Lindau综合征一例

Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging

  • 摘要: VHL(von Hippel-Lindau)综合征是一种罕见的常染色体显性遗传病。其临床表现复杂且多样,主要表现为视网膜、中枢神经系统、肾脏、胰腺等部位的多发肿瘤,患者常需进行全身多脏器评估。碳酸酐酶Ⅸ在VHL相关病变中普遍表达,68Ga-NY104作为一种新型小分子示踪剂,可对碳酸酐酶Ⅸ阳性病灶进行全身成像。本文报道一例32岁女性VHL综合征患者,先后行18F-FDG PET/CT和68Ga-NY104 PET/CT评估病灶,结果发现后者在更多种类的病灶(包括肾脏、胰腺、肝转移病灶及小脑病灶)中存在摄取。本文就该患者相关病灶的评估过程展开讨论,以期为探索VHL综合征患者的“一站式”评估手段提供借鉴。

     

    Abstract: VHL (von Hipple-Lindau) syndrome is a rare autosomal dominant genetic disease with complex and diverse clinical manifestations, which primarily presents as multiple tumors in the retina, central nervous system, kidneys, pancreas, and other areas. Patients often require comprehensive multi-organ assessment. Carbonic anhydrase Ⅸ (CAⅨ) is ubiquitously expressed in VHL-related lesions, and 68Ga-NY104, a novel small-molecule tracer, can perform whole-body imaging of CAⅨ-positive lesions. This case report introduces a 32-year-old female patient with VHL syndrome who underwent sequential 18F-FDG PET/CT and 68Ga-NY104 PET/CT for lesion assessment. Notably, 68Ga-NY104 PET/CT demonstrated uptake in a broader range of lesions (including renal, pancreatic, hepatic metastatic lesions and cerebellar lesions). This article discusses the process of evaluating the relevant lesions in this patient, with the aim of exploring a "one-stop" evaluation tool for patients with VHL syndrome.

     

/

返回文章
返回